Current methods have poor predictability and rely heavily on animal use.
90% of drugs that enter clinical trials never make it to the market, resulting in significant revenue losses for the pharmaceutical industry.
One-third of these failures are attributed to drug-induced side effects, primarily due to toxicity.
Current evaluation methods are overly simplistic, lack predictive accuracy, and heavily rely on animal studies.
Our solution
Versatile HTS drug screening measuring tiny forces from cells to ensure cardiac drug safety.
By increasing the probability of clinical success in cardiovascular applications, we reduce the risk of costly failures early in the drug discovery process.
